RNA Virus Gene Signatures Detected in Patients With Cardiomyopathy After Chemotherapy; A Pilot Study

Kyle Varkoly, Shaoyuan Tan, Roxana Beladi, David Fonseca, Isabela Rivabem Zanetti, Simona Kraberger, Chintan Shah, Jordan R. Yaron, Liqiang Zhang, Michael Juby, Ayman Fath, Sriram Ambadapadi, Melanie House, Paul Maranian, Carl J. Pepine, Arvind Varsani, Jan Moreb, Stacey Schultz-Cherry and Alexandra R. Lucas

Background: Viral infections are pervasive and leading causes of myocarditis. Immune-suppression after chemotherapy increases opportunistic infections, but the incidence of virus-induced myocarditis is unknown.

Objective: An unbiased, blinded screening for RNA viruses was performed after chemotherapy with correlation to cardiac function.

Methods: High-throughput sequencing of RNA isolated from blood samples was analyzed following chemotherapy for hematological malignancies (N = 28) and compared with left ventricular ejection fraction (LVEF).

Results: On initial rigorous analysis, low levels of influenza orthomyxovirus and avian paramyxovirus sequences were detectable, but without significant correlation to LVEF (r = 0.208). A secondary broad data mining analysis for virus sequences, without filtering human sequences, detected significant correlations for paramyxovirus with LVEF after chemotherapy (r = 0.592, P < 0.0096). Correlations were similar for LVEF pre- and post-chemotherapy for orthomyxovirus (R = 0.483, P < 0.0421). Retrovirus detection also correlated with LVEF post (r = 0.453, p < 0.0591), but not pre-chemotherapy, but is suspect due to potential host contamination. Detectable phage and anellovirus had no correlation. Combined sequence reads (all viruses) demonstrated significant correlation (r = 0.621, P < 0.0078). Reduced LVEF was not associated with chemotherapy (P = NS).

Conclusions: This is the first report of RNA virus screening in circulating blood and association with changes in cardiac function among patients post chemotherapy.
INTRODUCTION

The use of chemotherapy in treatment for neoplastic disease is associated with frequent side effects and non-therapeutic toxicities (1–3). Chemotherapy associated cardiac toxicity is well-described for some chemotherapeutic agents, however, for many agents the cause of cardiac toxicity is not defined (1–3). Chemotherapy-associated heart failure has considerable associated mortality and morbidity. Amongst 3,234,256 cancer patients in the United States, 38% have died from cancer and about 1 in 3 have died from cardiovascular disease (CVD). Among the deaths from CVD, 76% were in patients younger than 35 years. The incidence of all chemotherapy-associated cardiotoxocities is reported to be ~10% in all treated patients, and this is projected to increase as more patients receive chemotherapy (1–3).

Chemotherapy induces leukocyte cytotoxicity and immune suppression with increased risk of opportunistic infections, including bacteria, fungi and viruses (4–6). Viruses are the most common cause for myocarditis in patients without cancer or chemotherapy (7–9) and myocarditis is linked to a wide array of viruses, in some cases with severe heart failure (10–17). While opportunistic bacterial and fungal infections are frequently reported after chemotherapy and immunosuppression, opportunistic viral infections are less often reported. Herpesvirus, hepatitis B/C, influenza and parainfluenza viruses, respiratory syncytial virus (RSV), and retrovirus infections have been reported after chemotherapy (7–9), but the role of viruses in myocarditis in immunosuppressed patients after chemotherapy has not been studied. Opportunistic viral infection after chemotherapy is thus predicted to contribute to heart damage and heart failure.

Among the RNA viruses, Coxsackie virus B3 (CVB3), human parvovirus B19 (B19V), measles, retroviruses and influenza viruses have been implicated in myocarditis among other viruses, and these viruses have been detected after chemotherapy (7–16). B19V and the enterovirus, coxsackievirus, are considered leading causes of viral myocarditis (7–15). DNA viruses are also linked to myocarditis, specifically cytomegalovirus (CMV), Epstein bar virus (EBV), human herpes simplex virus-6 (HHV6) also cause myocarditis (17–19). In the past year, the RNA virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has also been implicated in acute myocarditis (14–16). Viral infections thus present a risk for myocarditis after immune suppression with chemotherapy.

In patients with chronic unexplained heart failure positive for B19V and treated with intravenous immunoglobulins (IVIG), a significant decrease in B19V load has been observed with improved cardiac function, symptoms, and decreased end diastolic volume (8). Other treatments that selectively target specific viruses, such as acyclovir that inactivates herpes simplex virus (HSV) DNA polymerase for herpes myocarditis or antiretroviral therapy for human immunodeficiency virus (HIV) infections have proven beneficial (8–19). Development of new vaccines to target viral infections are highly effective as for SARS-CoV-2 and COVID-19, but viruses with the potential to cause chemotherapy induced myocarditis must be identified in order to develop effective vaccines and treatments.

Accordingly, we postulated that immune suppression caused by chemotherapy, or by the cancer itself, will increase susceptibility to viral infections, and therefore myocarditis. This study presents an unbiased, blinded screen for RNA viruses in blood samples obtained from patients after chemotherapy for hematological malignancies. In this pilot study, reductions in measured left ventricular ejection fraction (LVEF) on 2D echocardiogram were correlated with measured levels of detected RNA virus gene signatures. To the best of our knowledge, this is the first screen for detectable RNA virus sequences in blood samples from cancer patients with evidence for myocarditis and reduced LVEF after chemotherapy. Information on opportunistic viral infections seen after immune suppression and chemotherapy will foster a defined preventative approach, such as development of vaccines or treatment with specific antiviral agents designed to reduce the risk of cardiac damage.

MATERIALS AND METHODS

Patient Population

Twenty-eight patients were enrolled in the Cardio-Oncology (AL) and the Hematologic Malignancies / Stem Cell Transplantation clinics (SC, JM) at the University of Florida after written informed consent. All patients and samples were assigned a randomized number after informed consent. The study was approved by the Institutional Review Boards (IRB) at all institutions involved in the study.

Patient ages ranged from 18 to 85 years; all had a diagnosis of cancer and a range of chemotherapeutic agents including dexamethasone, lanolidomide, rituximab, bortezomib, and cyclophosphamide, as well as combinations as noted (Table 1; Figure 1). The majority of patients had a history of hematological malignancy (25/26 hematological malignancy and 1/26 breast cancer) (Table 1). Six patients had a history of prior diagnosed ischemic heart disease, one with documented coronary artery disease and stent implant. Of the enrolled patients, 26 had complete viral sequencing (ST, SS-C) (Table 1). Eighteen patients had LVEF measured post chemotherapy, 22 patients had...
| Patient ID | Diagnosis | Age | Chemotherapy | Repeat chemotherapy | Stage | Diagnosis of prior heart disease | Ejection fraction (EF) prior to chemotherapy | Ejection fraction (EF) post chemotherapy |
|-----------|-----------|-----|--------------|---------------------|-------|-------------------------------|---------------------------------------------|---------------------------------------------|
| PJ0266_R2 | Multiple myeloma (MM) | 70–85 | Velcade and dexamethasone (2010–2012) 12/7/2012 (ASCT)→velcade maintenance (2013 till 1/2015) | None | IIIA | No | 60 | 30 |
| PJ0267_R2 | Follicular lymphoma | 80–85 | Bendamustine and rituximab(1/19/2016–4/12/2016) f/b rituximab 8/2016–1/2018 | Rituximab | IIA | IHD | 60 | 40 |
| PJ0268_R2 | Multiple myeloma (MM) | 60–65 | Revlimid, velcade, dexamethasone (1st)→CVD | CVD | IIIB | No | 60 | 50 |
| PJ0269_R2 | Chronic lymphocytic leukemia (CLL) | 75–80 | Ibrutinib | NA | NA | IHD | 60 | NA |
| PJ0270_R2 | Multiple myeloma (MM) | 70–75 | Revlimid, velcade | NA | IIIA | IHD | 60 | NA |
| PJ0271_R2 | Multiple myeloma (MM) | 70–75 | Velcade, dexamethasone→pomalidomide, dexamethasone | NA | IA | No | 60 | NA |
| PJ0272_R2 | Mantle cell lymphoma | 50–55 | Rituximab, fludarabine, cyclophosphamide→busulfan, cyclophosphamide, vincristine (conditioning)→rituximab maintenance | NA | IVA | No | 60 | 60 |
| PJ0273_R2 | Multiple myeloma (MM) | 50–55 | Velcade, revlimid, dexamethasone (2014)→revlimid (2015, 2016)→melphalan and transplant | Revlimid, transplant | NA | No | NA | 60 |
| PJ0274_R2 | Multiple myeloma (MM) | 45–50 | RVD | RVD, ASCT, velcade | IIIA | No | 60 | 65 |
| PJ0275_R2 | Multiple myeloma (MM) | 70–75 | CTX/velcade | Dexc, CTX, VCR, Mel | IIA | IHD | 30 | 40 |
| PJ0276_R2 | Multiple myeloma (MM) | 70–72 | RT, CVD | Dara/Velcade/Dexa | IIIA | No | 60 | NA |
| PJ0277_R2 | Multiple myeloma (MM) | 50–55 | RVD-CVD, revlimid maintenance, relapse #1, Kyprolis, pomalyst, VBCP | VBCP, Dara | IA | No | 55 | 55 |

(Continued)
| Patient ID | Diagnosis | Age | Chemotherapy | Repeat chemotherapy | Stage | Diagnosis of prior heart disease | Ejection fraction (EF) prior to chemotherapy | Ejection fraction (EF) post chemotherapy |
|------------|-----------|-----|--------------|---------------------|-------|-----------------------------------|------------------------------------------|------------------------------------------|
| PJ0278_R2  | Multiple myeloma (MM)-KLC | 50–55 | CVD | Revlimid, velcade, melflufen, Dexa | IIIB (III) | No | 35 | 45 |
| PJ0279_R2  | Multiple myeloma (MM)-PCL-LLC | 65–70 | CVDX 4 | Revlimid, prednisone | NA | No | 60 | 40 |
| PJ0280_R2  | Multiple myeloma (MM)-KLC | 65–70 | CVD X 4 | Revlimid | IIIA (I) | No | 60 | ND |
| PJ0281_R2  | Multiple myeloma (MM)-KLC | 65–70 | VD X 6 | None | IB (I) | No | NA | 70 |
| PJ0282_R2  | Multiple myeloma (MM)-lgG kappa | 75–80 | VTD, RVD | CVD, PD, PD+Elo, Dara, Dara+Velcade | IIIA (?) | No | 60 | 60 |
| PJ0283_R2  | Multiple myeloma (MM)-igA Lambda | 65–70 | CVD | Revlimid maintenance | IIIA (III) | No | 60 | ND |
| PJ0284_R2  | Multiple myeloma (MM)-lgG lambda, Acute lymphocytic leukemia (ALL) | 60–65 | VD | Revlimid maintenance | IIIA (III) | No | 60 | 55 |
| PJ0285_R2  | Multiple myeloma (MM)-lgG kappa | 70–75 | CVD | Revlimid, RVD, Kyprolis, pomalidomide | IIIA (?) | No | 55 | 20 |
| PJ0286_R2  | Multiple myeloma (MM)-lgG lambda | 70–75 | Thal/Dexa | Revlimid, CTX, RCD, high dose kyprolis | IIIA (III) | No | 60 | 55 |
| PJ0287_R2  | Multiple myeloma (MM)-lgG kappa | 70–75 | VAD | Revlimid maintenance, velcade/pomalidomide/dexa Dara, CTX, CVD,PD, VBCP,Kyprolis, VTD-PACE | No | 55 | 25% |
| PJ0288_R2  | Cirrhosis, DCIS, CAD | 50–55 | TAM | NA | NA | IHD | 65 | 60 |
| PJ0289_R2  | Multiple myeloma | 70–75 | Velcade and dexamethasone (2010–2012) – 12/7/2012 (ASCT) > revlimid maintenance (2013 till 1/2015) | NA | NA | No | NA | NA |
| PJ0290_R2  | Follicular lymphoma | 80–85 | Bendamustine and rituximab(1/19/2016 - 4/12/2018) f/b rituximab 8/2016- 1/2018) | Rituximab | IIA | IHD | 60% | 40–45% |
| PJ0291_R2  | Multiple myeloma | 60–65 | Revlimid, velcade, dexamethasone (1st) – VCD | NA | NA | NA | NA | NA |

dexa, dexamethasone; RVD, revlimid, velcade, dexamethasone; ASCIT, autologous stem cell transplant; CTX, cyclophosphamide; DCIS, ductal carcinoma in situ; VCR, vincristine; CVD, velcade, cyclophosphamide, dexamethasone; Mel, melphalan; Dara, daratumumab; VD, velcade and dexamethasone; RT, radiation therapy; VBCP, vincristine, BCNU, cyclophosphamide, and prednisone; Thal/Dex, thalidomide and dexamethasone; PD, pomalidomide and dexamethasone; PD+ Elotuzumab, PD and Elotuzumab; VTD, velcade, thalidomide and dexa; VAD, vincristine, Adriamycin and dexamethasone; RCD, revlimid, cyclophosphamide and dexa; VTD-PACE, Velcade, thalidomide, dexamethasone, platinum, Adriamycin, cyclophosphamide, and etoposide; TAM, tamoxifen.
FIGURE 1 | Bar graphs demonstrating mean LVEF ± SE with chemotherapy. No significant change in LVEF, as assessed by ANOVA, was detected for treatments with dexamethasone (A), lenalidomide (B), rituximab (C), bortezomib (D), cyclophosphamide (E), cancer diagnosed (F), or gender (G). Simple regression analysis demonstrates a significant correlation between LVEF post chemotherapy and increased age (H).

LVEF measured before chemotherapy, and 16 had both. One patient had confirmation of LVEF by cardiac catheterization. Chemotherapy was recorded for each patient. Echocardiograms were ordered by the attending physician based upon perceived clinical risk, but were not mandated. Cardiac dysfunction was defined as a decrease in ejection fraction (EF) <45% as demonstrated on echocardiography. LVEF data was available but more comprehensive data such as fractional shortening was not provided.

Virome Sequencing of Blood Samples
Blood samples were obtained 2–4 weeks after chemotherapy, once informed consent was obtained. Venous blood was collected in clinic at 2–4 weeks after the last chemotherapy in tubes containing 3 mL of Ethylenediaminetetraacetic acid (EDTA). RNALater (Life Technologies, Bleiswijk, The Netherlands) was added at a ratio of 2:1 RNALater to whole blood and samples stored at −80°C until analysis. Blood samples were anonymized and were sent to St Jude's Hospital (SCC, ST); where investigators were masked to cancer type, chemotherapy, and LVEF findings.

Samples were fragmented prior to RNA extraction as previously described (20). RNA was isolated using the QIAamp cador Pathogen Mini kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. First strand synthesis was completed using the random-primer technique described by Wang et al. (21). Briefly, Super Script III (Invitrogen, Carlsbad, CA, USA) first strand synthesis was carried out using primer A (5′-GTTTCCCCAGTCAGATTANNNNNNNN), followed by Sequenase (Affymetrix, Santa Clara, CA, USA) for second strand synthesis. Finally, PCR amplification utilized Primer B (5′-GTTTCCCCAGTCAGGATA) for 40 cycles. Samples were electrophoresed in an agarose gel to confirm product.

Samples were run on a 1% agarose gel and imaged to confirm the presence of DNA (between 500 bp and 1 kb). To prepare for sequencing, samples were purified using AMPure XP beads (Beckman Coulter, Brea, CA, USA) followed by analysis on a Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). A Nextera DNA library preparation kit (Illumina, San Diego, CA, USA) was used for sample genome sequencing using the Illumina MiSeq Amplicon application for virome reference genomes. Quality control of input nucleic acid and final libraries were checked using Agilent TapeStation 4200.

Bioinformatics Analysis
In an initial analysis, Illumina sequencing data sets were examined for viral pathogen detection. The quality of raw reads was assessed using FastQC (version 0.11.9) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Trimmomatic was used to trim the adapters from the paired-end reads (22). Taxonomic classification was performed for blood samples using Kraken2 (version 2.0.7b). Illumina sequencing data sets were initially analyzed for detection of RNA viruses (23–25). The RNA viral reads that were viral-like were also checked using BLASTn against a viral RefSeq database. Sequencing data is available, Bioproject accession number NCBI, PRJNA794842, temporary submission ID SUB10902989, release date: 2022-01-06.

For the broader viral RNA sequence analysis (SS-C, ST), a custom viral database, containing complete viral genomes cross referenced to RefSeq (ftp://ftp.ncbi.nlm.nih.gov/refseq/release/)
High Throughput Sequencing of RNA Virus in Blood Samples From Patients

Low levels of RNA virus sequences were detected in blood samples isolated from patients post chemotherapy. Detection of virus sequences using a strict, blinded analysis with either Blastn or Kraken 2 programs, and removing all potential contaminating human sequences, detected low levels of paramyxovirus and orthomyxovirus, as representative of potential opportunistic infections. The avian Avulavirus, a paramyxovirus, and Influenza A, an orthomyxovirus, were consistently identified on sequence analysis using both methods for RNA Seq analysis (Blastn and Kraken 2), indicating low levels of these RNA viruses after chemotherapy. The paramyxovirus avian Avulavirus and the orthomyxovirus Influenza A were the most frequently identified sequences.

Effects of Chemotherapy on Strict RNA Virus Sequence Read Detection

Potential correlations were assessed for detected RNA virus sequences and treatments with individual chemotherapeutic agents. Levels of virus sequences detected were increased with bortezomib and dexamethasone (Figure 2), however, there was only a trend toward increased detection of virus sequences in blood samples; \( p = 0.0623 \) for orthomyxovirus detection (Figure 2A), \( p = 0.1726 \) for paramyxovirus detection (Figure 2B) and \( p = 0.0767 \) for retrovirus sequences (Figure 2C) after bortezomib and \( p = 0.1061 \) for paramyxovirus (Figure 2D) after dexamethasone, none reaching significance. Analysis of a combined count of all detected RNA virus sequences in patients with bortezomib chemotherapy again detected a borderline increase \( (p = 0.053) \) (Figure 2E). Lenolidomide and cyclophosphamide treatment had no clear trend nor significant change in RNA virus gene sequence detection. In contrast, rituximab treatment was associated with a non-significant trend toward decreased virus sequence detection (not shown). Detection of RNA virus sequences in blood samples from cancer patients was not linked to gender \( (p = 0.1028, \text{ Figure 2F}) \) nor age \( (p = 0.245, \text{ Figure 2G}) \).

Initial Strict Analysis of RNA Virus Sequence Detection and Cardiac Function After Chemotherapy

On an initial rigorous, or strict, analysis, removing all potential contaminating human, bacterial or phage sequences, RNA virus sequences in the paramyxovirus (28) and orthomyxovirus (29) families were detected. Virus sequence detection was read blinded by four investigators (ST, SS-C, AV, AL). No significant correlations were detected for measured LVEF post chemotherapy; \( r = 0.177 \) for paramyxovirus \( (p = 0.4961, \text{ Figure 3A}) \), and \( r = 0.208 \) for orthomyxovirus \( (p = 0.4229, \text{ Figure 3B}) \). Screening for LVEF and a combined analysis of paramyxovirus and orthomyxovirus virus sequences detected a minimal, but again non-significant, increase in the correlation with reductions in LVEF reported on 2D echo post chemotherapy \( (r = 0.233, p = 0.3732, \text{ Figure 3C}) \). This would suggest that RNA virus gene signatures are detectable at low levels in blood samples.
from patients with reduced LVEF post chemotherapy, but do not have a significant correlation for reduced LVEF for individual detectable viruses in this small patient cohort.

Secondary Custom Database Analysis of RNA Virus Sequence Detection and Cardiac Function After Chemotherapy

A secondary, broad, customized Kraken2 database was next designed to detect a wider spectrum of RNA virus sequences as a metagenome analysis platform. This secondary analysis was performed without rigorous filtering of potential human genome sequences, and accepting both unidirectional as well as bidirectional reads. With this broad analysis an increased correlation was detectable for RNA virus sequences (Illustrated via Pavian software, Supplementary Figure 1). Bidirectional reads were used for analysis of correlations between detected virus gene signatures with measured LVEF post chemotherapy. Correlations of virus sequence detection with LVEF recorded prior to chemotherapy was used as a control to assess changes in LVEF prior to treatment with chemotherapy.

Paramyxovirus sequence detection and retrovirus sequence detection, using bidirectional reads from this more permissive analysis, had increased correlation when comparing LVEF post chemotherapy and LVEF measured pre chemotherapy; For paramyxovirus the correlation increased from \( r = 0.484 \) pre chemotherapy LVEF to \( r = 0.592 \) for LVEF measured post chemotherapy, with a clear increase in significance. Albeit both achieve significance.

Conversely, orthomyxovirus sequence detection, specifically for influenza A, had similar correlations when comparing paramyxovirus sequence reads to LVEF measured prior to or after chemotherapy \( (r = 0.513 \text{ pre}, P < 0.0248 \text{ and } r = 0.483 \text{ post}, P < 0.0421) \). Although both analyses for influenza A reached significance prior to or after chemotherapy, the fact that there was a significant and greater correlation prior to chemotherapy would suggest no specific association between orthomyxovirus detection and developing cardiac dysfunction after chemotherapy. Overall, orthomyxovirus and paramyxovirus sequences were again detected in this broad, less strict analysis, but with increased numbers of detectable reads using this custom platform.

Other RNA virus sequence reads were also detected using this broad analysis (Figure 5). One of the most prominent was the retrovirus HERV K (30). For retrovirus sequences, the correlation increased from \( r = 0.034 \) for LVEF measured pre chemotherapy \( (P = 0.8904, \text{ non-significant}) \) to \( r = 0.453 \) post chemotherapy with a borderline trend toward significance \( (P = 0.0591, \text{ Figure 5C}) \). Retrovirus sequences detected were predominantly human endogenous retrovirus K (HERV K), a retrovirus commonly detected in the human genome. Retrovirus sequences may represent activation from the native human cell genome, during the stress of cancer chemotherapy or extrinsic infections.

Among other sequences detected there were Molivirus, Pandoravirus and Pandoravirus dulcis, Lambdina fiscellaria
nucleopolyhedrovirus, Leukania separata nucleopolyhedrovirus, and several phage including Proteus virus mirabilis Isfaham, Aeromonas virus 25AhydR2PP and Aes 12, Caulobacter virus CcrBL10, Vibrio phage Eugene 12A 10, Streptomyces virus Izzy, and Pseudomonas phage OBP and PAJU2. None of these additional virus sequence reads demonstrated significant correlations for changes in LVEF post or even pre chemotherapy for hematological cancers (Figure 5 illustrates some of these analyses). For these virus sequences compared to LVEF post chemotherapy, the following r values were obtained: Molivirus r = 0.251, P = 0.3306; Pandoravirus and Pandoravirus dulcis r = 0.015, P = 0.9538; Lambdina fiscellaria nucleopolyhedrovirus r = 0.435, P = 0.3289; Leukania separata nucleopolyhedrovirus r = 0.114–0.201, P = 0.4372–0.6725; and several phage including Lactococcus phage BK5-T r = 0.228, P = 0.3625; Streptomyces virus Izzy r = 0.221, P = 0.4104; Proteus mirabilis virus Isfaham r = 0.433, P = 0.0826; Aeromonas virus 25AhydR2PP r = 0.447, P = 0.1088; Aes 12 r = 0.124, P = −0.6483; Caulobacter virus CcrBL10 r = 0.225, P = 0.3849; Vibrio phage Eugene 12A 10 r = 0.376, P = 0.5429; Pseudomonas phage OBP and PAJU2, r = 0.240–0.356, P = 0.1927–0.3536. A circular DNA Anellovirus, signature was detected in one patient with multiple myeloma and demonstrated no correlation.
A potential correlation between changes in LVEF pre and post chemotherapy with an analysis of a combined RNA virus sequence reads for virus sequence detection where trends toward increased RNA viral sequence correlations with reduced LVEF were demonstrated was then examined. A combined read for detected paramyxo- orthomyxo- and retro-virus sequences was assessed using this broad screen (Figure 4D). On this final analysis of combined RNA virus sequences for each sample, the correlation increased from $r = 0.233 \ (p = 0.3732)$ for pre chemo LVEF to $r = 0.621 \ (P < 0.0078)$ for post chemo LVEF, a markedly significant increase. Thus, increased detection of three detectable RNA virus sequence reads, paramyxovirus, orthomyxovirus- and retro-viruses after chemotherapy did demonstrate an apparent significant association with measured reductions in LVEF after chemotherapy (Figure 4D).

**DISCUSSION**

Dilated cardiomyopathy in cancer patients is a critically important complication after chemotherapy produced by cardiotoxicity with associated increased mortality (1–3). Immunosuppression with secondary opportunistic viral infection increases the risk for virus-induced myocarditis and heart damage after chemotherapy (4–9). Individual chemotherapeutic regimes have proven cardiotoxicity, but there are multiple molecular mechanisms for cardiac damage that differ for individual chemotherapeutic agents and some have no known etiology for cardiotoxicity (31–35). Viral infections are a leading cause for myocarditis in patients without cancer or chemotherapy (7–16, 36) and immunosuppression after chemotherapy increases the risk for opportunistic viral infections. We have performed a pilot study to screen for potential correlations between RNA virus sequences detected in blood samples and reduced LVEF post chemotherapy in patients with hematological tumors.

Chemotherapy is used for both hematological cancers and solid tumors with proven cytotoxicity, with a variety of non-therapeutic and potentially adverse side effects. Myocardial toxicity leads to left ventricular dysfunction (LVD), heart failure (HF), endothelial dysfunction, thrombogenesis, ischemia, vasoconstriction, pericardial disease, hypertension, and rhythm disturbances (1–3, 31–35). Incidence and cardiotoxic effects vary with individual chemotherapy agents. The incidence of LVD is 3–26% for Doxorubicin (anthracycline), 7–28% for Cyclophosphamide, 17% for Ifosfamide, 1–3% for Bevacizumab 2–28% for Trastuzumab therapy and 0.5–1.7% for Imatinib mesylate therapy (1, 2). Causes for cardiac toxicity varies from direct cardiomyocyte toxicity to vascular injury. Several mechanisms have been proposed for each class of agent, but individual chemotherapeutic reagents have differing molecular targets and reported causes for heart damage; there is, as might be expected, no unifying mechanism. The mechanism underlying anthracycline-induced cardiotoxicity has been reported as interference with topoisomerase II beta and secondary free-radical formation; apoptosis; transcriptional changes in intracellular adenosine triphosphate (ATP); reduced sarcoplasmic reticulum calcium-ATPase expression; prolonged depression in cardiac glutathione peroxidase
activity; and respiratory defects associated with mitochondrial deoxyribonucleic acid damage (12, 31–35). Cyclophosphamide-induced cardiotoxicity is postulated to be caused by endothelial injury through toxic metabolites that damage cardiomyocytes and secondary intracapillary microemboli and coronary vasospasm (1, 2). The mechanism of HF associated with bevacizumab is believed to be associated with uncontrolled HTN and inhibition of vascular endothelial growth factor (VEGF)/VEGF receptor signaling (1–3). Damage to the myocardium after treatment with chemotherapy thus has differing etiologies dependent upon the underlying cancer, treatment used, and the cause is incompletely defined for many newer chemotherapies. The potential for viral infection and secondary myocarditis after immunosuppression with chemotherapy for cancer has not been systematically examined as a potential cause for cardiomyopathy after chemotherapy.

In this study we measured RNA virus sequences in blood samples obtained from patients after chemotherapy using RNA Seq screening. RNA isolates were assessed both by an initial rigorous analysis that removed any potential human sequence contamination as well as with a subsequent broader, customized virome analysis. This was an unbiased screen for the detection of RNA virus sequences in venous blood samples in cancer patients receiving chemotherapy. On the initial more rigorous analysis, both paramyxovirus and orthomyxovirus sequences were detectable, but had no clear correlation with changes in LVEF (Figure 3). The orthomyxovirus Influenza A has a well-known association with viral myocarditis, but demonstrated similar correlations with LVEF measured prior to, or after, chemotherapy (6–9). Both paramyxovirus and orthomyxovirus families have been reported as causes for myocarditis in patients without known prior cancer or chemotherapy. The detectable sequences for orthomyxovirus matched to influenza A (29) and those for paramyxovirus with avulavirus (28). On a secondary broad analysis using a customized screen, we were able to detect larger numbers of RNA virus sequences for orthomyxovirus influenza A and paramyxovirus Avulavirus, as well as a larger array of RNA viruses including retroviruses, insect viruses and phage. In this second analysis we identified correlations between the detected paramyxovirus and retrovirus with changes in LVEF.

The increase in the paramyxovirus Avulavirus, sequences does demonstrate an increase in sequence detection and reduced LVEF after chemotherapy, with a greater correlation for post chemotherapy LVEF than for pre-chemotherapy LVEF. Orthomyxovirus influenza A was also detected, but with similar detected sequence counts and correlations for LVEF measured pre- or post-chemotherapy (Figure 4B); this correlation was stronger for pre-chemotherapy. Influenza is a common upper respiratory infection and the detection of this orthomyxovirus may be attributed to the prevalence of influenza A virus in the general population, with a generalized increase in an immunocompromised cohort. This suggests a general association of influenza A, the orthomyxovirus, with a reduction in LVEF that is unrelated to chemotherapy. The paramyxovirus Avulavirus sequence detection was also detectable, but the correlation was greater for LVEF measured after chemotherapy, albeit a small increase (Figure 4A). On the secondary, broader analysis, the greatest increase in correlation was seen with the HERV K retrovirus sequence on the post chemotherapy sample. Simple regression analysis for pre-chemotherapy LVEF analysis exhibited a flat, unresponsive regression with no evidence for correlation with LVEF pre chemotherapy, but with a clear inverted, negative correlation for detected HERV K sequences with post-chemotherapy LVEF (Figure 4C).

Retroviruses are reported to represent up to 8% of the human genome (37–41). Retrovirus sequence detection may represent activation of latent human retroviruses rather than opportunistic infection, as has been reported. Retrovirus K reads may represent reactivation from the human genome induced by the stress from chemotherapy and/or cancer. Blast confirmation indicated that all reads belonged to the human genome suggesting reactivation rather than de novo infections. HERV-K is the most transcriptionally active retrovirus in man, representing up to 8% of the human genome, and thus may also represent a contamination. HERV-K has been associated with neurodegenerative disorders, cancer, and an overall higher tumor burden (38–41). HERV K genes, like nuclear protein-1, has important roles in the generation of reactive oxygen species and other tumorigenic characteristics that may act in synergy with chemotherapeutics to decrease LVEF. HERV-K has also been reported to be upregulated after chemotherapy and could suggest that the stress of chemotherapy or the immunosuppression may have induced increased HERV-K expression.

Phage infect bacteria and alter bacterial responses after chemotherapy. We detected some phage sequences and these might be considered contaminants, as are the pandoraviruses. However, recent reports have demonstrated high levels of phage in many organs outside the gut (42, 43). Increased levels of phage are reported in the circulating blood in patients with increased gut permeability in leukemic patients where “leaky gut” is suspected to allow phages to translocate from the gut to the plasma (43). In this study, no correlation was uncovered between the detected phage sequences and insect virus reads with LVEF post chemotherapy (Figure 5). No correlation was found between anellovirus and reduced LVEF. These identified virus reads likely represent incidental detection of DNA viruses during analysis of RNA virus cDNA.

Bortezomib was associated with a borderline increase in detection of viral sequences (P = 0.0532). Other than age, none of the other parameters, chemotherapeutic agent, gender, cancer diagnosis and none of the other chemotherapeutic drugs demonstrated clear correlations with reduced LVEF pre- or post-chemotherapy.

This study was realized as an unbiased survey, a pilot study, to detect RNA virus sequences in blood samples in post chemotherapy patients with hematological cancers. In this study we were able to detect paramyxovirus, orthomyxovirus, and retroviruses in venous blood samples taken post chemotherapy for hematological malignancy. With a broad analysis, correlations were detected with LVEF measured post chemotherapy. This is, however, limited to a correlation without a definitive cause-and effect. A comprehensive analysis of correlations between detected virus sequences and reduced LVEF with scheduled blood samples, LVEF analysis, and heart damage markers prior to and after chemotherapy should be considered and has the potential to demonstrate chemotherapy induced
immune suppression and the risk of heart damage due to viral infection and/or reactivation.

LIMITATIONS OF STUDY

This study is limited by the small numbers of patients studied, variability in temporality of blood sample collection, as well as an incomplete data set for echocardiogram measured LVEF and longer term follow up for cardiac function. A control group of patients not receiving chemotherapy is not available, however the pre-treatment LVEF analysis by 2D echo provide an internal control. Echocardiograms were ordered at the discretion of the attending clinic physician and not all patients had LVEF measured.

CONCLUSIONS

In summary, low levels of RNA virus sequences are detectable in venous blood samples taken from patients with hematological cancers after chemotherapy. Analysis of these detected RNA virus sequences suggest that there is increased detection of RNA virus sequences in blood samples from patients after chemotherapy. Chemotherapeutic immune suppression increases the risk for chemotherapy induced myocarditis and cardiomyopathy with reduced LVEF. A comprehensive, structured study of cancer patients for sequential detection for RNA virus sequences after chemotherapy and correlation with LVEF analysis at predetermined follow up times, as well as an analysis for other markers for cardiac damage and immunosuppression is needed. A structured sequential analysis, as well as a comparison to patients without chemotherapy, will allow identification of opportunistic viral infections and identify potential approaches to prevent or treat viruses identified as risk factors for myocarditis and cardiomyopathy after chemotherapy.

CLINICAL PERSPECTIVES—TRANSLATIONAL OUTLOOK

Further investigation into the role of RNA viruses as a significant underlying etiology for myocarditis and cardiomyopathy after chemotherapy with associated immunosuppression is needed.

REFERENCES

1. Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management-Part 1. J Am Coll Cardiol. (2017) 70:2536–51. doi: 10.1016/j.jacc.2017.09.1096
2. Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Trifiletti DM, Chinchilli VN, et al. Fatal heart disease among cancer patients. Nat Comm. (2020) 11:1–8. doi: 10.1038/s41467-020-15639-5
3. Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, et al. Mechanisms clinical course of cardiovascular toxicity of cancer treatment I. Oncol Semin Oncol. (2019) 46:397–402. doi: 10.1053/j.seminoncol.2019.10.006
4. Morrison VA. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Inf Dis. (2014) 59:S360–4. doi: 10.1093/cid/ciu592

Understanding the role of virus induced myocarditis and cardiomyopathy after chemotherapy will allow for further treatment, both preventative through vaccines and for selective anti-viral treatment.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are publicly available. This data can be found here: NCBI, BioProject, PRJNA79842.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Biodesign Institute, ASU IRB and Department of Medicine, Shands Hospital, University of Florida. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

KV, ST, RB, MJ, SS-C, CP, and AL designed the experiment and wrote the manuscript. ST, SA, CS, MH, SS-C, and AL managed participant recruitment and were responsible for sample acquisition and preservation. AL, ST, KV, RB, SK, JY, LZ, MJ, PM, and AV analyzed and interpreted the data. All authors contributed to manuscript revision, provided important intellectual contributions, and approved the submitted version.

FUNDING

This work was supported by Biodesign, ASU startup funding (AL), American Heart Association (AL), National Institutes of Health (AL), and St Jude Children’s Research Hospital (SS-C).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.821162/full#supplementary-material

SUPPLEMENTARY Figure 1 | Pavan software illustrations of detected RNA virus reads detected based on Kraken 2 analyses for all individual patient samples.

REFERENCES

5. Nesher L, Rolston KV. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection. (2014) 42:5–13. doi: 10.1007/s15010-013-0525-9
6. Hijano DR, Maron G, Hayden RT. Respiratory viral infections in patients with cancer or undergoing hematopoietic cell transplant. Front Microbiol. (2018) 9:3097. doi: 10.3389/fmicb.2018.03097
7. Abelmann WH. Virus and the heart. Circulation. (1971) 44:950–6. doi: 10.1161/01.CIR.44.4.950
8. Hazebroek M, Dennert R, Heymans S. Virus infection of the heart - unmet therapeutic needs. Antivir Chem Chemother. (2012) 22:249–3. doi: 10.3851/IMP2047
9. Van Linthout S, Tschöpe C. Viral myocarditis: a prime example for endomyocardial biopsy guided diagnosis and therapy. Curr Opin Cardiol. (2018) 33:325–33. doi: 10.1097/HCO.0000000000000515
10. Dennert R, Velthuis S, Schalla S, Eurlings L, van Sylen RJ, van Paassen P, et al. Intravenous immunoglobulin therapy for patients with idiopathic...
cardiomyopathy and endocardiacmyopathy biopsy-proven high PVB19 viral load. Antivir Ther. (2010) 15:193–201. doi: 10.3851/IMP1516
11. Zhou L, He X, Gao B, Xiong S. Inhibition of histone deacetylase activity aggravates Cossackievirus B3-induced myocarditis by promoting viral replication and myocardial apoptosis. J Virol. (2015) 89:10512–23. doi: 10.1128/JVI.01028-15
12. Wang D, Chen Y, Jiang J, Zhou A, Pan L, Chen Q, et al. Carvedilol has stronger anti-inflammation and anti-virus effects than metoprolol in murine model with coxsackievirus B3-induced viral myocarditis. Gene. (2014) 547:195–201. doi: 10.1016/j.gene.2014.06.003
13. Chang S, Zhi C, Li H, Huang D, Fan Q, Cui J, et al. Umifenevir effectively inhibits IL-10 dependent persistent Cossackie B4 virus infection. Antiviral Res. (2017) 141:165–73. doi: 10.1016/j.antiviral.2017.02.018
14. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Federica M, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. (2020) 116:1666–87. doi: 10.1093/cvr/cvaa106
15. Hendren NS, Dzazeri MH, Bozkurt B, Cooper LT Jr. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. (2021) 141:1903–14. doi: 10.1161/CIRCULATIONAHA.120.043739
16. Quagliariello V, Bonelli A, Caronna A, Conforti G, Iovine M, Carboni A, et al. SARS-CoV-2 infection and cardiocoonology: from cardiometabolic risk factors to outcomes in cancer patients. Cancers. (2020) 12:3316–41. doi: 10.3390/cancers12113136
17. El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus myocarditis using next generation sequencing. Virol J. (2018) 15:207. doi: 10.1186/s12985-018-0130-2
18. Wu Y-T, Li X, Liu Z-l, Xu Z, Dai W, Zhang K, et al. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: systematic review and meta-analysis. PLoS ONE. (2017) 12:e0179680. doi: 10.1371/journal.pone.0179680
19. Legoff J, Resche-Rigon M, Bouquet J, Robin M, Naccache SN, Séverine Mercier-Delarue S, et al. The eukaryotic gut virome in hematopoietic cell transplantation: new clues in enteric graft-versus-host disease. Blood. (2016) 128:6224–36. doi: 10.1182/blood-2016-06-688432
20. Handous I, Achour B, Marzouk M, Rouis S, OHazgui O, Ines Brini I, et al. Co-infections of human herpesviruses (CMV, HHV6, HHV-7 and EBV) in non-transplant acute leukemia patients undergoing chemotherapy. Viril J. (2020) 17:37. doi: 10.1182/s12985-020-01302-4
21. Wu Y-T, Li X, Liu Z-l, Xu Z, Dai W, Zhang K, et al. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: systematic review and meta-analysis. PLoS ONE. (2017) 12:e0179680. doi: 10.1371/journal.pone.0179680
22. Bolger AM, Lobse M, Usadel B. Trimomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. (2014) 30:2114–20. doi: 10.1093/bioinformatics/btu170
23. Boonham N, Kreuze J, Winter S, van der Vlugt R, Bergevoet J, Tomlison J, et al. Methods in virus diagnostics: From ELISA to next generation sequencing. Virus Res. (2014) 186:20–31. doi: 10.1016/j.virusres.2013.12.007
24. Huang B, Jennison A, Whiley D, McMahon J, Hewitson G, Graham R, et al. Illumina sequencing of clinical samples for virus detection in a public health laboratory. Sci Reports. (2019) 9:5409. doi: 10.1038/s41598-019-41830-w
25. Takeuchi S, Kawada J-I, Okuno Y, Horiba K, Suzuki T, Torii Y, et al. Identification of potential pathogenic viruses in patients with acute myocarditis using next generation sequencing. J Mol Virol. (2018) 90:1814–21. doi: 10.1002/jmv.25263
26. Derrick E, Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome Biol. (2019) 20:257. doi: 10.1186/s13059-019-1891-0
27. Breitwieser FP, Salzberg SL. Pavan: interactive analysis of metagenomics data for microbiome studies and pathogen identification. Bioinformatics. (2020) 36:1303–4. doi: 10.1093/bioinformatics/btt715
28. Ashraf A, Mahboob S, Andleeb R, Ijaz MU, Shah MS. Status updates of Newcastle disease and amelioration effects of medicinal plants against Newcastle disease virus: A review. Acta Virol. (2018) 62:3–15. doi: 10.4149/av_2018_010
29. Rezkalla SH, Klontz RA. Influenza-related viral myocarditis. WMJ. (2010) 109:209–13.